



Abstracts from the HTAi 2024 Meeting in Seville,  
Spain

International Journal of

# Technology Assessment in Health Care



# International Journal of Technology Assessment in Health Care

Official Journal of Health Technology Assessment International

## Editor-in-Chief

Wendy Babidge, BApp Sci (Hons), Ph.D., Grad Dip Bus, PGCert HEHCP York

General Manager Research, Audit and Academic Surgery, Royal Australasian College of Surgeons

Adjunct Professor, University of Adelaide

24 King William St, Kent Town, South Australia 5067, Australia

Email: eic.ijtahc@cambridge.org

**Aims and Scope:** *International Journal of Technology Assessment in Health Care* serves as a forum for the wide range of stakeholders, including policy makers, academics, patients, health technology developers and health professionals interested in the intended and unintended consequences of health technology. Articles on any aspect related to health technology assessment (HTA) are welcomed.

The journal covers the development, evaluation, diffusion and use of health technology, as well as its impact on the organization and management of health care systems and public health. The journal particularly considers articles in the following areas: Evaluation or development of methods, processes, or policies used in HTA; primary research on the effects of implementing HTA or their findings; and novel research within particular HTAs that provides learning for International Journal of Technology Assessment in Health Care serves as a forum for the wide range of stakeholders, including policy makers, academics, patients, health technology developers and health professionals interested in the intended and unintended consequences of health technology. Articles on any aspect related to health technology assessment (HTA) are welcomed.

The journal covers the development, evaluation, diffusion and use of health technology, as well as its impact on the organization and management of health care systems and public health. The journal particularly considers articles in the following areas: Evaluation or development of methods, processes, or policies used in HTA; primary research on the effects of implementing HTA or their findings; and novel research within particular HTAs that provides learning for HTA.

**Publishing, Advertising, and Subscription Offices:** Cambridge University Press, One Liberty Plaza, Floor 20, New York, NY 10006, U.S.A. (for U.S.A., Canada, and Mexico); or Cambridge University Press, Journals Fulfillment Department, UPH, Shaftesbury Road, Cambridge CB2 8BS, UK (for U.K. and elsewhere).

**2020 Subscription Information:** *International Journal of Technology Assessment in Health Care* (ISSN 0266-4623) is

published bimonthly in February, April, June, August, October, and December by Cambridge University Press, One Liberty Plaza, Floor 20, New York, NY 10006; Cambridge University Press, Journals Fulfillment Department, UPH, Shaftesbury Road, Cambridge CB2 8BS, UK. Annual institutional subscription rates for Volume 36 (2020): Institutions online only US \$654.00, and online only UK and elsewhere £376.00. Individuals online only US \$380.00, and online only UK and elsewhere £214.00. Single part: US \$125.00 in the U.S.A., Canada and Mexico; UK £72.00 and elsewhere. Online only for all institutions. Print editions ceased in 2014. Back volume prices are available upon request. *International Journal of Technology Assessment in Health Care* and other Cambridge journals can be found at <http://journals.cambridge.org>

## © Cambridge University Press & Assessment 2024

All rights reserved. No part of this publication may be reproduced, in any form or by any means, electronic or otherwise, without permission in writing from Cambridge University Press. Policies, request forms, and contacts are available at: <http://www.cambridge.org/rights/permissions.permission.htm>

Permission to copy (for users in the U.S.A.) is available from Copyright Clearance Center, <http://www.copyright.com>, email: [info@copyright.com](mailto:info@copyright.com).

Postmaster: Send address changes in the U.S.A. and Canada to: *International Journal of Technology Assessment in Health Care*, Journals Department, Cambridge University Press, One Liberty Plaza, Floor 20, New York, NY 10006, U.S.A. Send address changes elsewhere to: *International Journal of Technology Assessment in Health Care*, Cambridge University Press, Journals Fulfillment Department, UPH, Shaftesbury Road, Cambridge CB2 8BS, UK.

**Founding Editors:** Egon Jonsson and Stanley J. Reiser

# Contents

## Oral Presentations

OP01 Impact Of Cost Heterogeneity On Assessing The Value Of Gene Therapies .....	s1
OP02 Osseointegrated Prosthetic Implants (Direct Skeletal Attachment) For People With Lower-Limb Amputation: A Hospital-Based Health Technology Assessment.....	s1
OP03 Regionalization And Patient-Centered Care: A Rapid-Realist Review And Implications For Health Technology Assessment.....	s2
OP04 The Modernized Cardiff Model: Multifaceted Modeling In The Era Of Cardiovascular-Kidney-Metabolic Syndrome .....	s2
OP05 Efficiency Frontier Analysis Of Ciltacabtagene Autoleucel For Relapsed/Refractory Multiple Myeloma In Brazil .....	s3
OP06 Utilizing Health Technology Assessment Outputs To Develop Health Technology Management Protocols In The Irish Setting.....	s3
OP07 Technical Aspects Of Artificial-Intelligence-Based Tools Applied In Health Technology Assessment Processes: A Scoping Review .....	s4
OP08 Health Technology Assessments Of Artificial Intelligence: Special Considerations And Development Of A Checklist.....	s4
OP09 Investigating The Nature And Scope Of Innovative Payment And Pricing Schemes For Health Technologies .....	s5
OP10 Affordability Decision Rules: Systematic Review And Categorization Of Budget Impact Thresholds For 174 Countries Based On International Practices.....	s5
OP11 Assessing Patient And Societal Unmet Needs: The Needs Examination, Evaluation And Dissemination (NEED) Assessment Framework .....	s6
OP12 Identification Of Patient And Societal Needs In Melanoma: Application Of The Needs Examination, Evaluation And Dissemination (NEED) Assessment Framework.....	s6
OP13 Improving Case Finding For Celiac Disease In Children And Adults: Evidence Synthesis And Economic Modeling .....	s7
OP15 Cost-Effectiveness Of Quantitative Fecal Immunochemical Tests For Detecting Suspected Colorectal Cancer In The Context Of Colonoscopy Capacity Constraints.....	s7
OP16 “Progress Is Impossible Without Change”: A Case Study To Feasibly Incorporate Environmental Sustainability In Health Technology Assessment .....	s8
OP17 Methods To Measure The Environmental Impacts Of Health Technologies And Include Them In Economic Evaluations: A Scoping Review.....	s8
OP18 Incorporating Environmental Impacts In The Economic Evaluation Of Health Technology Assessment: State Of The Art And Challenges .....	s9
OP19 Multiple-Criteria Decision Analysis: Techniques To Support Environmental Sustainability Framework Development In Health Technology Assessment.....	s9
OP20 Incorporating External Information In Survival Extrapolation Using A Simplified Bayesian Approach .....	s10
OP21 Long-Term Cost-Effectiveness Of IDegLira Versus Basal-Bolus Insulin Therapy In Patients With Type 2 Diabetes In Chinese Setting .....	s10
OP22 Productivity Benefits Of Modifying Cardiovascular Disease Risk In Type 2 Diabetes In Australia: A 10-Year Prediction Dynamic Model .....	s11
OP23 Key Challenges For The Appraisal Of Disease-Modifying Dementia Drugs .....	s11
OP24 How Does Robotic-Assisted Surgery Real-World Evidence Complement Randomized Controlled Trials Evidence? A Systematic Literature Review And Meta-Analysis.....	s12
OP25 Rapid Molecular Tests For Detecting Multidrug-Resistant Microorganisms: An Overview Of Systematic Reviews Within A Living Evidence Project .....	s12
OP26 Artificial Intelligence For Literature Screening And Selection: Does The Evidence Support Its Use In Systematic Literature Reviews?.....	s13
OP27 Artificial Intelligence Use In Health Technology Assessment In Low- And Middle-Income Countries .....	s13
OP28 Digi-HTA: The Assessment Method For Digital Health Technologies In Finland.....	s13
OP29 Determinants Of The Financial Impact Of Rare Disease Drugs In Italy: Differences Between Expected And Observed Pharmaceutical Expenditure.....	s14
OP31 Monitoring Of The Budget Impact Determinants Of Incorporated Technologies For Rare Diseases In The Brazilian Health System .....	s14
OP32 Identification Of Factors Alongside Costs And Effectiveness For The Technology Assessment Of Comprehensive Genomic Profiling: A Systematic Review .....	s15
OP33 Advancing Patient Experience Data Implementation In Reimbursement Decision-Making: Insights On Challenges And Opportunities From Multistakeholder Interviews.....	s15
OP34 Implications Of The New EU Regulation For Orphan Drug Health Technology Assessments In Ireland .....	s16

OP35 Early Access To Medicinal Products In France: A Positive Evaluation Two Years Into The New Framework .....	s16
OP36 Real-World Data From Early Access Programs In France: A Two-Year Review .....	s17
OP37 The Spanish Health Technology Assessment Network Methodological Approach For The Utilization Of Real-World Data In The Preadoption Phase .....	s17
OP38 Perinatal And Infant Mental Health Care: International Guideline Recommendations And Situation In Austria.....	s18
OP39 Efficiency Frontier For Relapsing-Remitting Multiple Sclerosis In Brazil: An Approach To System Sustainability.....	s18
OP40 Circumstances That Unlock Payer Acceptability Of Innovative Trial Designs: A Case Study And Primary Research-Based Global Analysis .....	s19
OP41 Pharmaceutical Technologies Conditionally Approved By The National Institute For Health And Care Excellence: A Critical Analysis.....	s19
OP42 A Budget Impact Analysis Of The Introduction Of Noninvasive Prenatal Testing To Korean National Health Insurance .....	s20
OP43 Incorporating Mathematical Modeling To Improve Accuracy Of Budget Impact Analysis: Using Screening For Hepatitis C As An Example.....	s20
OP44 Cost-Of-Illness And Cost-Consequence Analysis Of Dementia In Italy.....	s20
OP45 Incorporation Of The Tetravalent Dengue Vaccine In The Brazilian Public Health System: A Cost-Benefit Analysis.....	s21
OP46 A New Modular Approach To Updating National Institute For Health And Care Excellence Manuals.....	s21
OP47 New Health Technology Assessment Framework For Digital Health Technologies .....	s22
OP48 Establishing The Implant Subsidy List In Singapore: A Collaborative Approach Between Health Technology Assessment And National Procurement Agencies.....	s22
OP49 Are Propensity-Score-Based Adjusted Indirect Comparisons Feasible For All European Joint Clinical Assessments Based On Non-Randomized Data? .....	s23
OP50 NICE Listens: Engaging The Public On How Environmental Sustainability Should Be Considered In Health Technology Assessment .....	s23
OP51 Strategies For Training Laypeople To Participate In Health Technology Assessment: A Scoping Review .....	s23
OP52 How Will European Joint Clinical Assessment Impact National Decision-Making? .....	s24
OP53 An Actionable And Legible Toolbox For The Appraisal Of Healthcare Innovations Developed Through Nationwide Stakeholder Collaboration .....	s24
OP54 Different Perceptions Of Additional Benefit By Payers And Providers: Discrepant Voting Within G-BA's Benefit Appraisals .....	s25
OP55 Transferability Of Economic Models Within Health Technology Assessment In Central And Eastern Europe: Bridging The Gap .....	s25
OP56 Hospital-Based Health Technology Assessment: Barriers And Facilitators In France, Hungary, Italy, Kazakhstan, Poland, Switzerland, And Ukraine .....	s26
OP57 Comparing Institute For Clinical And Economic Review Comparative Effectiveness Assessments And Federal Joint Committee Added Benefit Assessments .....	s26
OP58 Diagnostics And Treatments For COVID-19: Update From A Living Systematic Review Of Economic Evaluations .....	s27
OP61 Target Trial Emulation To Determine The Population-Level Cost-Effectiveness Of Multigene Panel Sequencing For Advanced Melanoma .....	s27
OP62 Economic Evaluations Submitted For Reimbursement To The Brazilian Unified Health System: A Meta-Epidemiological Study .....	s28
OP63 A European Value Assessment Framework For Next-Generation Sequencing And Comprehensive Genomic Profiling Oncology Diagnostics.....	s28
OP64 Risk-Based Prioritization In Patients Referred For Transcatheter Aortic Valve Implantation: A Simulation Study .....	s29
OP65 Focusing On What Matters Most: A Public Dialogue On How NICE Should Prioritize Topics In Health Technology Assessment .....	s29
OP67 "Black Box Bottleneck" Paradigm And Transparency Issues On Artificial-Intelligence-Based Tools In Health Technology Assessment: A Scoping Review.....	s29
OP68 Adaptation Of Processes For HTA Of Digital Health Technologies Based On Artificial Intelligence .....	s30
OP69 Are Artificial-Intelligence-Based Literature Reviews Accepted By Health Technology Assessment Bodies? .....	s30
OP70 Implementation Of An Online Consultation Hub To Facilitate Consumer Engagement In Health Technology Assessment Processes.....	s31
OP71 Patient Disease Strategy: A New Operational Framework For Collecting And Applying Patient Experience Data Into Clinical Development Programs .....	s31
OP72 Patient Organization Submissions Made To A National Health Technology Assessment Agency In Ireland.....	s32
OP73 Navigating The Advanced Therapy Medicinal Products (ATMPs) Conundrum: Insights From ATMPs Withdrawn In The European Market.....	s32
OP74 A Comprehensive Health Technology Assessment Framework For Omics Technologies In The Spanish Setting .....	s33

OP75 Pharmaceutical Innovativeness Index: Evaluation Of Pharmaceutical Innovation In Lung Cancer Treatment Drugs Approved Between 2011 And 2021 .....	s33
OP76 Cost-Effectiveness Of Offering Human Papillomavirus Self-Sampling To Non-Attendees Of Organized Primary Cervical Cancer Screening In Germany .....	s34
OP79 Innovations In Measuring And Valuing Outcomes: Generating Preferences For The EQ Health And Wellbeing Short.....	s34
OP80 Generating Patient Preference Evidence For Health Technology Assessment: A Sustainable Roadmap .....	s35
OP81 Experience Matters: A Discrete Choice Experiment Exploring Patient Preferences For Heart Valve Procedures .....	s35

## Oral Presentations (online)

OD01 Delays In Funded Access To Medicines: A Global Perspective.....	s35
OD02 Developing Components For A National Strategy For Heart Valve Disease In Canada .....	s36
OD04 The EQ-5D-5L Value Set For Ghana.....	s36
OD05 Frameworks For Synthesizing Qualitative Evidence In Health Technology Assessment: A Scoping Review .....	s37
OD07 Disaggregation Of The Costs Of Pharmaceutical Research And Development.....	s37
OD08 Health Technology Assessment Timelines And Outcomes Of Common Compounds In France, Germany, Sweden, And Poland From 2014 To 2022 .....	s38
OD09 How Are Population/Intervention/Comparator/Outcomes Criteria For Pharmaceutical Assessments Determined Around The World?.....	s38
OD11 Application Of Natural Language Processing To Predict Final Recommendation Of Brazilian Health Technology Assessment Reports.....	s39
OD12 Large Language Models As Powerful Tools In Health Technology Assessment .....	s39
OD14 Harmonization Of HTA For Digital Health Technologies: The EU-Funded European Digital Health Technology Assessment Project .....	s40
OD15 Multiparametric Magnetic Resonance Imaging In Biopsy-Naive Patients: A Real-World Evidence For Decision-Making In Prostate Cancer Pathway.....	s40
OD16 Assessing Technical Aids In Europe: Are There Any Specific Health Technology Assessment Methods To Assess Technical Aids?.....	s41
OD17 Future Health And Economic Burden Of Cardiovascular Disease In Type 2 Diabetes In Australia From 2021 To 2031 .....	s41
OD18 Surrogate Measures And The Health Technology Assessment Of Cancer Drugs In Ireland: A Retrospective Analysis, 2017 to 2022 .....	s42
OD19 Future Health And Economic Burden Of Cardiovascular Disease In Type 2 Diabetes In Qatar, From 2023 To 2032 .....	s42
OD22 Innovating Patient Involvement In Health Technology Assessments To Enable More Sustainable Involvement From Patient Stakeholders.....	s43
OD23 Evolving Prostate Cancer Screening Strategies In Germany: A Cost-Utility Analysis Comparing Traditional And Emerging Modalities.....	s43
OD24 Scalability Analysis Of Multimodal Prehabilitation For Frail Elderly Patients Before Elective Surgery In Germany .....	s44
OD26 Comparing Health Technology Developers' Proposed Indication To An Estimated Indication Generated By An International Horizon Scanning Database .....	s44
OD27 Estimating The Causal Effect Of Adaptive Treatment Strategies Using Longitudinal Observational Data .....	s45
OD28 Towards Implementing New Payment Models For The Reimbursement Of High-Cost, Curative Therapies: Insights From Semi-Structured Interviews.....	s45
OD29 From Listening To Lift Off: Developing A Three-Year Public Involvement And Engagement Strategy For NICE .....	s46
OD30 Clinician-Driven Health Technology Assessment: National Cancer Medicines Review For Off-Label Uses And On-Label Off-Patent Uses In NHSScotland .....	s46
OD31 Value-Based Healthcare And Health Technology Assessment: Opportunities For Implementing A Colorectal Cancer Patient-Centered Care System .....	s47
OD32 Single Nucleotide Polymorphism Marker Analysis In Donor-Derived Cell-Free DNA For Solid Organ Transplantation (Next-Generation Sequencing): Systematic Review .....	s47
OD33 Assessment Tool For MHealth Apps To Manage Depression (EvalDepApps Project) .....	s48
OD34 Consideration Of Medical Device Characteristics In Health Technology Assessment: A Gap In The Methods Guidelines And In Practice.....	s48
OD37 How The PICOTS-ComTeC Framework For Digital Health Interventions Can Be Useful For Health Technology Assessment.....	s49
OD38 Real-World Analysis Of First-Line Maintenance Treatment For Patients With Nonsquamous Advanced/Metastatic Non-Small-Cell Lung Cancer .....	s49

OD39 Evaluation Of Sustainability And Environmental Impact Measures In Health Technology Assessment Of Medical Technologies In Europe: Starting An Important Journey .....	s50
OD41 Conducting Systematic Reviews On Rare Diseases: Lessons Learned From The European Reference Networks Guidelines Programme .....	s50
OD43 The Growing Clinical And Economical Burden Of Chronic Kidney Disease In Brazil: An IMPACT CKD Analysis .....	s51
OD44 Consolidated Health Economic Evaluation Reporting Standards For Interventions That Use Artificial Intelligence (CHEERS-AI) .....	s51
OD45 Evaluating Quality In Health Economics: Quality Appraisal Checklist For Systematic Reviews Of Studies Eliciting Health State Utility Values .....	s52
OD46 Inequalities In Dementia: Identifying Instruments For Measurement .....	s52
OD48 Improving Public Understanding Of Health Technology Assessment Decisions.....	s52

## Poster Presentations

PP01 Early Health Technology Assessments Of Health And Well-Being Returns On Investment In The Biobanks.....	s53
PP02 The Application Of Care Pathway Analysis And Economic Modeling In Early Health Technology Assessment: Learnings From Two Projects .....	s53
PP03 Investigating Technological Strategies In The Hospital Setting: Insights From The Dutch Context .....	s54
PP04 Assessing The Utility Of Natural Language Processing In Generating A Granular Estimated Indication For A Horizon Scanning Database .....	s54
PP06 Incentives To Incorporate Innovation Into Care Delivery Processes: A Scoping Review And SWOT Analysis .....	s55
PP07 One Bad Apple Can Spoil The Barrel: Are We Effectively Evaluating Software As A Medical Device? .....	s55
PP08 Prognostic Factors For Survival In Adults With Burkitt Lymphoma: A Systematic Review And Meta-Analysis .....	s56
PP09 Fecal Immunochemical Tests For Patients With Symptoms Suggestive Of Colorectal Cancer: A Systematic Review And Multiple-Threshold Meta-Analysis.....	s56
PP10 Addressing The Challenge Of Environmental Sustainability Between Management And Health Technology Assessment At The Hospital Level.....	s57
PP11 Evaluating Environmental Sustainability In Health Technology Assessment: A Multisectoral Systematic Review.....	s57
PP12 Projecting The Potential Impact Of Disease-Modifying Therapies For Alzheimer's Disease On The Carbon Emissions From Hospital Bed-Days in the UK.....	s58
PP13 Cost-Effectiveness Analysis Of Antiandrogen Therapies For Metastatic Castration-Sensitive Prostate Cancer: The Brazilian Healthcare System Perspective .....	s58
PP14 Recombinant Human Erythropoietin For Sickle Cell Disease And Brazilian Healthcare System Sustainability: Cost-Effectiveness And Budget Impact Analysis.....	s59
PP15 Cost-Benefit Analysis Of An Antimicrobial Stewardship Program In A Cancer Setting In Qatar.....	s59
PP16 Vial Sharing And Wastage Are Familiar Concepts, But What About Pack Sharing And Wastage?.....	s60
PP17 Navigating Health Technology Assessment (HTA) Requirements During Development Through Early HTA Scientific Advice: Insights From Companies' Strategies, Challenges, And Priorities.....	s60
PP18 Red Flags For The Early Diagnosis Of Rare And Complex Connective Tissue And Musculoskeletal Diseases.....	s61
PP19 Time And Cost Savings Of Machine Learning And Artificial Intelligence (AI) In Systematic Reviews: A Case Study .....	s61
PP20 Health Technology Assessment To Sustain The Health Insurance Scheme: A Case Study On Anemia Treatment In Ghana.....	s62
PP21 Examining Clinical Evidence: Incorporation Of Medications For Ultra-Rare Diseases – Descriptive Analysis Of Conitec Reports (2012 to 2022) –Brazil .....	s62
PP22 A Dashboard To Support The Value Assessment Of Digital Health Technologies For Health Technology Assessment Agencies.....	s63
PP23 Machine-Learning-Based Evaluation Of Community Resilience Through Social Media During The First Post-COVID-19 Reopening In China.....	s63
PP24 Creating A Comprehensive Open-Access Health Technology Assessment (HTA) Policy Research Database Through Automated Data Extraction From HTA Reports .....	s64
PP25 Artificial Intelligence In Healthcare Decision-Making: Addressing Challenges, Ethical Considerations, And Bias .....	s64
PP26 Systematic Literature Review Of Funding Models For The Access To Drugs For Patients With Rare Diseases.....	s65
PP27 Evidence Quality and HTA outcomes in Reappraisals For Drugs For Rare Diseases In Germany .....	s65
PP28 The Final Arguments To Incorporate Or Not Incorporate Technologies For Ultra-Rare Diseases Into The Brazilian Public Healthcare System.....	s65
PP29 Social Preferences In Health Technology Assessments For Rare Diseases: A Systematic Literature Review Of New Analytic Approaches.....	s66



PP30 The Health System Impact Of Returning Rare Disease Variants As Secondary Findings From Genomic Sequencing: A Population-Based Model.....	s66
PP31 Logical Model Articulating Pharmacy Commissions And Hospital-Based Health Technology Assessment Nuclei: Collaborative Strategies For The Drug Selection.....	s67
PP32 Health Technology Assessment Regulation In Europe: Implications For A National Authority .....	s67
PP34 Impact Of The COVID-19 Pandemic On Depression Incidence And Healthcare Service Use Among Patients With Depression.....	s68
PP35 Keeping It Real Around The World: Comparing Real-World Evidence Guidance From Regulatory And Health Technology Assessment Bodies .....	s68
PP36 Real-world Effectiveness Of Umeclidinium And Umeclidinium/Vilanterol For Chronic Obstructive Pulmonary Disease: A Singapore Database Study .....	s69
PP37 Guidance On Using Hospital-Based Real-World Evidence In Health Technology Assessments For Oncology .....	s69
PP38 Assessment Outcome By Type Of Available Evidence: Retrospective Analysis Of Oncological Early Benefit Assessment Reports .....	s70
PP39 Co-Creation Of A European Digital Health Technology Assessment Framework: The EDiHTA EU-Funded Project.....	s70
PP40 The Use Of “Softer” Outcomes In The NICE Health Technology Assessment Process: The Case Of Multiple Sclerosis .....	s71
PP41 Enhancing Health Technology Assessment Through Behavioral Economics: A Strategic Approach To Sustainable Healthcare Innovation .....	s71
PP42 Implementing A Sustainable Enhanced Recovery From Surgery Pathway After Hip And Knee Arthroplasty: A Budget Impact Analysis .....	s71
PP43 Budget Impact Analysis Of Next-Generation Sequencing Coverage In Taiwan’s National Health Insurance .....	s72
PP45 Core Outcome Sets For Research And Core Outcome Sets For Routine Care: Do They Overlap? .....	s72
PP46 Economic Value Of Minimally Invasive Procedures: Examining Revolutionary And Evolutionary Devices In Aortic Stenosis And Benign Prostatic Hyperplasia .....	s73
PP47 The Role Of Target Product Profiles Within Health Technology Assessment: A Narrative Review And Case Study.....	s73
PP48 Cost-Effectiveness Of Mepolizumab In Children And Adolescents With Refractory Severe Eosinophilic Asthma In Brazil .....	s74
PP49 Prescribing Trends And Economic Impact Of Somatostatin Analogues In Acromegaly: A Threat To Brazil’s Public Health System Sustainability .....	s74
PP50 Facilitating Academic Life Science Innovation With Early Health Technology Assessment: A Survey Of Potential User Needs And Perceptions .....	s75
PP51 Pharmaceutical Innovativeness Index (PII): A New Framework For Assessing Health Technology Innovation Based On Therapeutic And Social Relevance.....	s75
PP52 Pharmaceutical Innovativeness Index – FDA-Approved Prostate Cancer Medications (2011 To 2021): A Case Study.....	s76
PP53 Potential Cost-Effectiveness And Innovation Headroom Of A More Accurate Companion Diagnostic For PD-L1 In Non-Small-Cell Lung Cancer .....	s76
PP54 Towards Equitable Pricing: Unraveling The Complexities Of External Reference Pricing In Medical Devices .....	s77
PP55 Health Technology Assessment Scoping Definition For Health Regulation.....	s77
PP56 National Immunization Technical Advisory Groups Are Essential For Successful Implementation Of The European Health Technology Assessment Regulation .....	s78
PP57 Outcomes Model For Assessing Strategies Improving In Vitro Fertilization Birth Rates .....	s78
PP58 Enhancing Health Technology Assessment Understanding Through Targeted Educational Programs .....	s78
PP59 Do Patient Contributions Matter? A Thematic Document Analysis Of NICE Ultra-Rare Disease Appraisals .....	s79
PP60 Enhancing Patient Empowerment: European Capacity Building Initiative And Curriculum Development In Health Technology Assessment Training .....	s79
PP61 A Decade Of Enhanced Patient And Citizen Involvement In Health Technology Appraisal In Scotland.....	s80
PP62 Improving Patients’ Access To Medicines Through Health Technology Assessment In Ukraine: Measuring The Impact Of The National HTA Roadmap .....	s80
PP63 Perspectives Of Physical And Organic Disability Organizations On Health Technology Assessment Processes .....	s81
PP64 Impact Of The Cost-Effectiveness Threshold On Drug Funding Recommendations: The Case Of Rare Diseases In Brazil.....	s81
PP65 How Does The Spanish Health Technology Assessment Network Assess The Value Of Robotic Surgical Platforms? A Review Of Challenges Faced .....	s82
PP66 International Horizon Scanning Initiative (IHSI) : Time to Review the Need for Stand-Alone National Horizon Scanning? .....	s82
PP67 From Insight To Foresight: Singapore’s Experience In Horizon Scanning Of Medical Technologies .....	s83

PP68 Successfully Streamlining New Medicines Assessments In Scotland: A Stakeholder Evaluation Of The Scottish Medicines Consortium's Abbreviated Submission Process.....	s83
PP70 Comparison Of Approval Dates Of New Substances Between The U.S. Food And Drug Administration And The European Medicines Agency .....	s84
PP71 Organizations Responsible For The Evaluation Of Health Technologies Globally: A Scoping Review .....	s84
PP73 Integrating Valid Recommendations In The Clinical Practice Guidelines Updating Process Using GRADE Methodology.....	s85
PP74 Are Commonly Used Cost-Effectiveness Thresholds Too Low? Empirical Evidence From Economic Studies On The Value Of Life .....	s85
PP75 Treatment Of Rheumatoid Arthritis In The Single Health System: Profile Of Medication Use And Expenses .....	s86
PP76 "It Is Better For Me To Die Than To Be Disgraced": Perceptions Of Worse-Than-Death Health States In Ghana .....	s86
PP77 Cost-Effectiveness Of The Dengue Vaccine (TAK-003) In Brazil .....	s87
PP78 Data Extrapolation With Survival Curves: An Alternative Approach With Aggregated Data.....	s87
PP79 Challenges With Integrating Early-Stage Cancer Trial Endpoints Into Economic Models: Review Of Canadian And International HTA Recommendations .....	s87
PP81 The Importance Of Networking To Produce Better Health Technology Assessment Evaluations: An HTA Guideline For Orthoses And Prostheses In Brazil .....	s88
PP82 Prevention And Intervention Software Applications For People At Risk Of Suicide: Effectiveness And Safety .....	s88
PP83 Building Resilient Capacity For The Diagnosis Of Cardiac Pathologies Through Telemedicine: Pilot Study.....	s89
PP84 Developing The Network For The Future Of Healthcare Through Telemedicine-Driven Diagnostic Innovation .....	s89
PP86 Development Of A Tool To Assist In The Identification Of Study Designs For The Purposes Of Health Technology Assessment .....	s90
PP87 A Descriptive Study Of The Use Of Data Visualization In Full Health Technology Assessment Reports: 2021 To 2023.....	s90
PP88 Breaking Boundaries In Health Technology Assessment: Quantifying Non-Traditional Value Of Medical Technology Through ExpertLink Remote Connectivity Solutions.....	s91
PP89 Artificial Intelligence And Health Technology Assessment: Playing Catch-Up .....	s91
PP92 Enhancing Patient Engagement In Health Technology Assessment: Identification Of Barriers, Facilitators, And Proposals For Improvement.....	s92
PP94 Chronic Obstructive Respiratory Disease Patients' Involvement In The Evaluation Of Transcutaneous Capnography In Primary Care .....	s92
PP96 Evaluating The Quality-Of-Life Impact Of Erythropoiesis-Stimulating Agents For Lower Risk (Low To Intermediate-1) Myelodysplastic Syndrome Patients .....	s93
PP97 Conduction System Pacing Implantation Through Electroanatomic Mapping-Guided Versus Fluoroscopy In Patients With Severe Bradyarrhythmias.....	s93
PP100 A Study On Health-Related Quality Of Life Among Patients With Advanced Gastric Or Gastro-esophageal Junction Adenocarcinoma .....	s94
PP101 A Review Of Health State Utility Values Associated With Herpes Zoster .....	s94
PP102 Sustaining Ghana's National Health Insurance Scheme: Leveraging The Role Of Priority-Setting Tools In Benefit Package Reviews.....	s95
PP104 Utility Of Chemiluminescence Detection Of Anti-Domain 1 $\beta$ 2 Glycoprotein I Antibodies In Antiphospholipid Syndrome .....	s95
PP105 Assessment Of Blood Biomarkers For The Diagnosis Of Alzheimer's Disease: From Promise To Reality.....	s96
PP106 Links Between Accuracy And Effectiveness Of Laboratory Diagnostic Tests: Health Technology Assessment Of Two Analytical Approaches For Glycated Hemoglobin.....	s96
PP107 Effectiveness And Safety Of Cytoreductive Surgery And Heated Intraperitoneal Chemotherapy For Pediatric Peritoneal Carcinomatosis: A Living Evidence Synthesis .....	s97
PP108 A Systematic Review Of Reactogenicity And Safety Of Recombinant Zoster Vaccine For Prevention Of Herpes Zoster In Adults .....	s97
PP109 Which Review Is Right For You? Choosing A Review Methodology .....	s97

## Poster Presentations (online)

PD01 Budget Impact Analysis Of Expanding Newborn Inherited Metabolic Diseases Screening In Shanghai, China .....	s98
PD02 Budget Impact Analysis: A Challenge To Incorporating Medications For Ultrarare Diseases In The Brazilian Healthcare System .....	s98
PD03 Exploring Expenditure On State Subsidized Medicines In Ireland Between 2018 And 2022: Special Focus On Cancer Drug Expenditure .....	s99
PD04 A Systematic Review Of Decision Analytical Modeling Studies Of Medicines In The Middle East.....	s99



PD06 Automated Systems For Hospital Inpatient Safety: A Cost-Utility Analysis .....	s100
PD07 Can Commencing Colorectal Cancer Screening At Age 45 Years Be A Good Investment? An Individual-Level Simulation Analysis In Germany .....	s100
PD08 Clinical And Cost Effectiveness Of Selected Diabetes Medicines In Ghana - An Adaptive Health Technology Assessment.....	s101
PD10 Cost Effectiveness Analysis Of Etranacogene Dezaparvovec Versus Factor IX Prophylaxis In Adult Men With Hemophilia B From Brazil .....	s101
PD11 Cost-Effectiveness Analysis Of Inclisiran For Treating Primary Hypercholesterolemia And Mixed Dyslipidemia In Singapore .....	s102
PD12 Cost Effectiveness Analysis Of Nivolumab Plus Ipilimumab For First-Line Treatment Of Advanced Non-Small Cell Lung Cancer In China .....	s102
PD13 Cost Effectiveness Of Imipenem-Cilastatin-Relebactam Compared With Colistina-Imipenem For Treating Confirmed Carbapenem Non-Susceptible Gram-Negative Bacterial Infections .....	s103
PD14 The Cost Effectiveness Of Robot-Assisted Gait Training For Patients In Japan With Subacute Hemiplegic Stroke .....	s103
PD15 Cost Effectiveness Of The Wolbachia Method For Dengue Control In Brazil.....	s104
PD18 Cytomegalovirus Prophylaxis With Valganciclovir For HIV-Immunosuppressed Patients: Cost Effectiveness And Budget Impact Analysis From The Brazilian Healthcare System Perspective .....	s104
PD20 Economic Assessment And Budget Impact Model Of Injectable Ganciclovir For Cytomegalovirus Infection In Immunosuppressed Patients In Brazil .....	s105
PD22 Economic Evaluation Of Polygenic Risk Scores In Clinical Practice: A Systematic Review.....	s105
PD23 Economic Evaluation Of Prophylactic Immunoglobulin Versus Prophylactic Antibiotics In Hematological Malignancies: Results From The RATIONAL Feasibility Trial .....	s106
PD24 Innovation In Chronic Obstructive Pulmonary Disease Care: Cost Effectiveness Of A New Self-Management Maintenance Program In The United Kingdom .....	s106
PD25 Innovation In Facial Palsy Treatment: The Costs And Benefits Of Telerehabilitation Introduced Into Physical Therapy Pathways.....	s107
PD26 Seeking Sustainability For The Brazilian Public Healthcare System: Cost-Utility Analysis Of Pembrolizumab For Advanced Non-Small Cell Lung Cancer.....	s107
PD27 The Cost Effectiveness Of Non-Hospital Cardiac Rehabilitation: A Systematic Review .....	s108
PD29 Using Different Parametric Distributions In Partitioned Survival Analysis: Impact On Incremental Cost-Utility Ratio In A Proportional Hazards Model.....	s108
PD30 How Is Sustainability Incorporated Into Healthcare Systems? A Progress Report Card For The EU5.....	s109
PD31 The Significant Societal And Environmental Impact Of Chronic Kidney Disease Over The Next Decade In Brazil .....	s109
PD32 Incorporating Environmental Factors Into Health Technology Assessment Submissions: A Scoping Review.....	s110
PD33 Using Environmental Impact Data To Support Health Technology Assessment At The National Institute for Health and Care Excellence: An Options Appraisal .....	s110
PD34 Ethics In Health Technology Assessment – A Case Study Of Prosthetic Care And Proposal For An Empirical Approach .....	s111
PD35 A Decade In Review: Assessing The Quality Of Clinical Evidence For Oncology Drugs Submitted To A National Health Technology Assessment Agency .....	s111
PD36 Assigning GRADE Levels To An Overview Of Reviews Using General Principles Identified From Current GRADE Guidelines .....	s112
PD37 Development Of A Tool For Quality Assessment Of Health Economic Evaluations.....	s112
PD38 Ensuring Study Validity To Inform Health Technology Assessments Globally.....	s112
PD39 First Approach For Assessing Statistical Significance In Industry Funded Matching-Adjusted Indirect Comparison Studies: A Scoping Review .....	s113
PD40 Pilot Healthcare Programs - Bridging The Evidence Gap For Innovative Technologies .....	s113
PD41 Quality Of Diagnostic Test Accuracy Systematic Reviews In Neglected Diseases Registered In PROSPERO: Meta-Epidemiological Review Of Methodological Compliance.....	s114
PD42 Should Antibiotics Be Used To Treat Recurrent Otitis Media In Children? Updating A Recommendation .....	s114
PD43 Single-Arm Studies In Literature Reviews: Trials Versus Case Series.....	s115
PD45 A Rapid Evidence Synthesis Method For Cancer Screening Recommendations In A Hospital Setting .....	s115
PD49 Developing Evidence-Based Optimal Testing Strategies To Monitor Long-Term Conditions In Primary Care .....	s115
PD50 Does The New Healthcare Reform Improve Job Satisfaction Among Village Clinic Doctors In China? A Meta-Analysis .....	s116

PD51 Effectiveness And Safety Of Vitamin D For COVID-19: A Living Evidence Synthesis Informing A Health Technology Assessment Report.....	s116
PD52 Evidence Review Of Universal Ultrasound Screening For Developmental Dysplasia Of The Hip In Infants.....	s117
PD54 Impact Of Experiencing Vaso-Occlusive Crisis In Patients With Sickle Cell Disease: Systematic Review And Meta-Analysis Of Prognostic Studies.....	s117
PD55 Living Recommendations Within A Type 2 Diabetes Mellitus Guideline.....	s118
PD56 Long-Term Use Of Lisdexamfetamine For Attention-Deficit/Hyperactivity Disorder: What Does The Evidence Say? .....	s118
PD57 Patient Involvement In The Development Of Clinical Practice Guidelines For Rare Diseases: A Systematic Literature Review.....	s119
PD58 The Repellent Effects Of <i>Cymbopogon Nardus</i> On <i>Aedes Aegypti</i> Mosquitoes: A Rapid Review .....	s119
PD59 Review Of The International Epidemiology Of Long COVID.....	s119
PD60 The Importance Of Systematic Reviews Addressing Questions Of Prevalence In Health Technology Assessment.....	s120
PD61 Thromboprophylaxis After Major Orthopedic Surgeries: Health Technology Assessment To Promote Access To Oral Anticoagulants.....	s120
PD62 Judicialization Of Health In A Brazilian University Hospital: How Can We Reduce The Budget Impact? .....	s121
PD64 Modeling Clinical And Economic Impact Of Integral, Transversal, And Multidisciplinary Management Of Aortic Stenosis In A Catalan Hospital.....	s121
PD65 How Methods Innovation In Health Technology Assessment Missed The Opportunity To Include Health Equity In The Value Puzzle .....	s122
PD66 Scalability Of Integral, Transversal, And Multidisciplinary Management Of Aortic Stenosis In Catalan Hospitals.....	s122
PD67 Real-World Evidence To Inform Reflexive Practice And Create Value In Lung Cancer Care.....	s123
PD68 A Cross-Cultural Validation Study Of The German And English Versions Of The ICEpop CAPability measure for Adults (ICECAP-A) .....	s123
PD69 Road Map Of Health Equity Considerations In Health Technology Assessments: Identifying The Evidence From Epidemiology To Health Economics.....	s124
PD70 A Mapping Study Of EORTC-QLQ-C30 To EQ-5D-5L Among Korean Patients With Non-Small Cell Lung Cancer.....	s125
PD71 Survival Outcomes And Adherence To Defined Daily Doses Of Imiglucerase: A 16-Year Brazilian Cohort Study In Gaucher Disease .....	s125
PD72 Are Patient Experience Data Currently Embedded In Reimbursement Decision-Making? An Analysis Of Belgian Reimbursement Documents .....	s125
PD75 Using The Quality-Adjusted Life-Year For Economic Evaluations Of Public Health Interventions: Benefits And Criticisms.....	s126
PD76 Cost-Effectiveness Analysis Of An Influenza Vaccination Program In Algeria, Egypt, Saudi Arabia, Turkey, and the United Arab Emirates .....	s126
PD77 Review Of Multicriteria Decision Analysis-Like Processes For Prioritization Of Newborn Bloodspot Screening Conditions .....	s127
PD80 Exploring Key Factors Influencing Patients' Antidepressant Preferences: Insights From A Multicenter Best-Worst Scaling Survey .....	s127
PD83 Medication Preferences Of Rural Patients With Chronic Disease: A Discrete Choice Experiment In An Eastern Province Of China.....	s128
PD85 Are Current Payment Models For Integrated Care Promoting The Uptake Of Medical Device Innovations? .....	s128
PD89 Guidance For Designing Pivotal Studies Of High-Risk Medical Devices By International Regulatory Authorities: A Systematic Review.....	s129
PD90 Use Of Medicinal Herbs In Natura By Pregnant Women In The Amazon Region .....	s129
PD91 Gaps And Challenges In The Health Technology Assessment Of Genetic And Genomic Applications: A Systematic Review .....	s130
PD92 Health Technology Assessment Of Genetic And Genomic Applications: A Proposal For A Standardized Approach .....	s130
PD93 Uncertainty Metric To Guide PICOS Assessment And Evidence Synthesis Planning For Joint Clinical Assessment Submission.....	s131
PD94 Adapting Existing Evidence-Based Clinical Practice Guidelines: A Case Example with Sexually Transmitted Infections Guidelines In Catalonia, Spain.....	s131
PD95 Enhancing Clinical Practice Guideline Development In Brazil: A Tutoring Program For Health Technology Assessment Centers .....	s132
PD96 Are Continuous Noninvasive Blood Pressure Monitoring Devices Accurate Enough To Replace Invasive Monitoring? A Rapid Review.....	s132
PD97 Comparison Of Clinical Outcomes Of Self-Expandable Versus Balloon-Expandable Valves For Transcatheter Aortic Valve Replacement: A Population-Based Cohort Study.....	s133
PD99 Effectiveness And Safety Of Bioelectrical Stimulation Techniques In Fibromyalgia: A Systematic Review.....	s133
PD101 Evaluating The Budget Impact Of Introducing RefluxStop™ As A Novel Treatment Option For Gastro-esophageal Reflux Disease In Italy.....	s134
PD102 Evaluating The Clinical Effectiveness Of Portable Ultrasonic Scalpels For Urological Surgery.....	s134
PD103 Pediatric Exoskeleton For The Treatment Of Spinal Cord Atrophy And Other Neuromuscular Diseases.....	s135

PD104 Percutaneous Ethanol Injection In Thyroid Nodular Pathology And Metastatic Cervical Adenopathies: A Systematic Review, Meta-Analysis, And Economic Evaluation .....	s135
PD108 Digital Transformation Of An Organization Supporting Informal Caregivers During Pandemic: Lessons Learned And Future Direction For A Sustainable Solution.....	s136
PD109 Health Vulnerability: Rethinking Intervention Strategies In A Health Maintenance Organization In Brazil.....	s136
PD110 Ward Round Woes: Accuracy Of Ward Round Documentation .....	s137
PD111 A Health Technology Management Approach To Dupilumab Reimbursement In Ireland – Data From Year One.....	s137
PD112 Calcitonin Gene-Related Peptide Monoclonal Antibodies Reimbursed Under A Managed Access Protocol In Ireland.....	s138
PD115 Digital Health Solutions: Health Technology Assessment Of Digital Platforms For Personalized Management, Education, And Support For People With Diabetes.....	s138
PD116 Development Of A Value Framework For The Appropriate Prescription Of High-Cost Cancer Drugs In A Cancer Center .....	s139
PD117 Proposed Matrix For Efficient Reassessment Of Selective Benefits.....	s139
PD118 Company-Led Submissions For Cancer Medicines: The Singapore Experience .....	s139
PD119 Interventions To Improve Long COVID Symptoms: A Systematic Review Of Randomized Controlled Trials .....	s140
PD122 Evaluating The Efficacy Of Cytokine Filtration In Cardiac Surgery For Endocarditis: A Comprehensive Study.....	s140
PD124 Genicular Artery Embolization For The Treatment Of Knee Osteoarthritis: A Systematic Review And Meta-analysis.....	s141
PD125 Safety, Efficacy, And Effectiveness Of Robotic Surgery In General And Digestive Surgery.....	s141
PD126 A Systematic Review Of Interval Cancer Rates In Colonoscopy Screening For Colorectal Cancer.....	s142
PD127 A Systematic Review Of The Clinical Effectiveness Of Recombinant Zoster Vaccine For Preventing Herpes Zoster In Adults .....	s142
PD128 Evaluating The Implementation Of An Abdominal Aortic Aneurysm Screening Program In Spain .....	s143
PD129 Extension Of An Influenza Vaccination Program To Include Those Aged 50 To 64 Years: A Rapid Health Technology Assessment Approach.....	s143
PD130 Health Technology Assessment Of Cervical Cancer Screening In Indonesia.....	s144
PD131 Literature Analysis And Hot Topics In Congenital Heart Disease Screening In China: A Bibliometrics Study Using CiteSpace .....	s144
PD132 A Target Trial Emulation Application Assessing The Survival Of Erythropoiesis-Stimulating Agents In Patients With Lower Risk Myelodysplastic Syndrome .....	s144
PD133 Exploring Real-World Data Based Financing Models For Lung Cancer Immunotherapy In The Czech Republic.....	s145
PD134 Projecting The 10-Year Cost Of Care Burden For Depression Until 2032 In Hong Kong: A Real-World Evidence Based Markov Model.....	s145
PD135 Real-World Evidence On The Effects Of Robotic Prostatectomy In Poland.....	s146
PD136 Re-evaluation Of Chest X-Ray Screening For Lung Cancer With Consideration Of Study Context.....	s146
PD137 Reviewing The Health Technology Assessment And Regulatory Policy Landscape On Acceptability Standards For Real-World Evidence - Initial Findings .....	s147
PD139 Investigation Of The Current Status Of New Health Technology Assessment In Korea And The Factors Influencing Assessment Results.....	s147
PD140 A Strengths, Weaknesses, Opportunities, And Threats Analysis Of Prehabilitation Before Elective Surgery For Frail Elderly Patients .....	s148
PD141 Health Technology Assessment Methodology Approach For Precision Personalized Medicine: An Innovative Public Procurement Case Study.....	s148
PD142 Implantable Neurostimulation Devices For The Treatment Of Drug-Resistant Pediatric Epilepsy .....	s149
PD144 Uncertainty In Precision Medicine: The Value Of Research To Support The Value Of Personalized Intervention Policies .....	s149
PD146 Can We Properly Evaluate Genetic And Genomic Applications? A Systematic Review Of Health Technology Assessment Reports .....	s150
PD147 Overview Of Multiplex Antigen Near-Patient Tests For Acute Respiratory Infections.....	s150
PD149 Comparison Of The Draft European Union Health Technology Assessment Template With Germany's AMNOG Template .....	s151
PD150 How Is Genetic Testing Evaluated? An Updated Systematic Review Of Assessment Frameworks .....	s151
PD151 Informal Networking For Health Technology Assessment Capacity Building In African Countries .....	s152
PD153 Horizon Scanning Analysis Of The Obesity Medicines Pipeline.....	s152
PD154 Horizon Scanning Report Identifying Technologies For Pediatric Neurological Trauma.....	s152

PD155 RedETS Horizon Scanning: Impact In The Decision-Making Process.....	s153
PD156 Scanning The Right Horizons: Does Singapore's Horizon Scanning Identify And Assess The Relevant Technologies? .....	s153
PD158 Optimizing The Management Of Patients With Mitral Regurgitation Beyond Technological Innovations: A Proposed Set Of Actions .....	s154
PD161 Distribution Patterns And Economic Assessments Of Gaucher Disease Therapies In Brazil: A National Health System Analysis (1999 to 2022).....	s154
PD165 To What Extent Do Health Technology Assessment Bodies Cross-Reference Each Other In Their Reports?.....	s155
PD166 Artificial Intelligence, Healthcare System Budget Cuts, And Flow of New Evidence: Moving To Living Health Technology Assessment Reform.....	s155
PD167 Charting A Sustainable Way To Subsidize Implants In Singapore.....	s156
PD168 Developing And Implementing A Value Framework For Rapid Health Technology Assessments: Enhancing Evidence-Informed Coverage In Resource-Constrained Settings .....	s156
PD169 Is China Embracing Innovation? An Analysis Of Early Access In The Boao Lecheng International Medical Pilot Zone .....	s157
PD170 Modification Of The All Wales Medicines Strategy Group Appraisal Process Provides Faster Access To Children's Medicines In Wales.....	s157
PD171 National Health Service Wales - First UK Nation To Approve Dostarlimab For The Treatment Of Rectal Cancer.....	s158
PD172 Off-Label Rituximab As A First-Line Immunosuppressant Treatment For Generalized Myasthenia Gravis In Wales .....	s158
PD173 Semi-Automation Of Systematic Literature Review Title And Abstract Screening Using Text Mining And Classification Techniques .....	s159
PD174 The Emerging Role Of National Health Service England In The UK – An Access Enabler Or Barrier For Innovations?.....	s159
PD175 Using Machine Learning To Optimize Systematic Literature Reviews.....	s160
PD177 The Effect Of COVID-19 On Cancer Screening In Brazil, Canada, And The USA: A Cross-National Study.....	s160
PD178 Impacts Of COVID-19 On Mental Health Services: Telepsychiatry Efficacy And Substance Use Disorder Challenges In The USA.....	s160
PD179 Navigating Health Crises In Emerging Economies: A Comprehensive Examination Of COVID-19's Influence On Health Care Access And Resilience.....	s161
PD180 Strategies To Minimize The Impact Of The COVID-19 Pandemic On People With Disabilities: Systematic Review And Deliberative Dialogues .....	s161
PD184 Health Technology Assessment (HTA) Topics That Respond To National Needs: Considerations Around The Topic Selection Process When Institutionalizing HTA.....	s162
PD185 Is The Incorporation Of Medications For Ultrarare Diseases In Brazil Predominantly Driven By Costs? A Shift In Paradigm.....	s162
PD186 Treat-To-Target In Gout: Are Private General Practitioners In Malaysia Riding The Evidence-Based Wave? .....	s163
PD187 Health Technology Assessment Training Program in Ukraine: An Example Of Collaborative Capacity Building .....	s163
PD188 Step-By-Step Introduction Of Hospital-Based Health Technology Assessment In Ukraine .....	s164
PD189 Strengthening Health Decision-Making: The Role Of Capacity Building In Health Technology Assessment In Latin America .....	s164
PD190 The Brazilian Health Technology Assessment Network Strategy: Capacity Building And Its Importance For The Sustainability Of The Public Health System .....	s165
PD191 Global Disparities In Bariatric Surgery Reimbursement: A Comparative Analysis Of 23 Countries .....	s165
PD192 Criteria For Decision-Making In Health Economic Evaluations: An Analysis Of Global Practices .....	s165
PD193 Submission Processes And Requirements For Health Technology Assessment In Australia, Canada, England, France, And Germany .....	s166
PD194 The Scenario Of Hospital-Based Health Technology Assessment In Brazil, Italy, And Poland .....	s166
PD195 Variation In Decision-Making And Market Access Routes For Vaccines: Insights From Seven Countries .....	s167
PD196 The Importance Of Promoting The Culture Of Health Technology Assessment Among Healthcare Professionals.....	s167
PD197 Improving The Impact Of Health Technology Assessment Reports: Experience Of The Synthesis In Catalonia .....	s168
PD198 A Review Of Regulatory Theory To Inform Discussion On Aligning Regulation And Health Technology Assessment Of Medical Devices .....	s168
PD199 Global Collaboration Post-Brexit: Do Project Orbis And The Access Consortium Improve Access In The UK Compared With Europe?.....	s168
PD200 Implications Of The European Artificial Intelligence Act For Health Technology Assessment.....	s169
PD201 Rare Disease Product Approvals: The Changing Regulatory And Health Technology Assessment Landscape Between 2013 And 2022.....	s169
PD202 Reimbursement Success For Pharmaceutical Products With Noncomparative Data: Are Health Technology Assessment Bodies Well Suited To Embrace Innovations?.....	s170

PD203 Comparison Of Health Technology Assessment Methodologies Across Australia, Canada, New Zealand And The United Kingdom: Implications For Future Collaboration .....	s170
PD204 Comparison Of Reimbursement Systems In France Denmark, Norway, And The United Kingdom - Possibilities Of Implementation In Poland .....	s171
PD205 “Medical Fund” – A Novel Approach To Granting Individuals Access To Cutting-Edge Therapies .....	s171
PD206 Health Technology Assessment And Decision-Making During The COVID-19 Pandemic: Analysis Of Processes And Results From 25 Health Ministries .....	s172
PD207 Modelling Co-Financing Scenarios To Address The Financial Challenges Of Implementing A Colorectal Cancer Screening Program For Private Insurance Beneficiaries.....	s172
PD208 Optimal Scheme For Molecular Diagnosis Of <i>BRCA1/2</i> Gene Mutations In Patients With Breast Cancer In Poland - Cost-Utility Analysis .....	s173
PD209 Social Burden Of Inflammatory Bowel Diseases In Poland: Impact Of Changes In Drug Programs On Social Security Expenditures .....	s173
PD210 Sustainable Innovation In UK Care Homes: Acoustic Monitoring Systems In A “Living Lab” Setting - Technology Assessment Example.....	s174
PD212 A Model-Based Study To Estimate Medicare Payment Methods With Chinese Characteristics – The Diagnosis Intervention Packet Policy.....	s174
PD213 An Unmet Health-Related Needs Evidence Database For Informing Policy And Innovation Decisions In Health Care.....	s175
PD214 Appraisal Of Reimbursement Thresholds For Medicines In Brazil’s Private Health System .....	s175
PD215 Assessing Drug Pricing Disparities In Brazil’s Public And Private Healthcare Sectors .....	s176
PD216 Efficiency Frontier Analysis: Supporting Sustainable Non-Small Cell Lung Cancer Healthcare Policies In Brazil.....	s176
PD218 Quantitative Analysis Of The Policy Text For Free Training Of Rural Order-Oriented Medical Students In China .....	s177
PD220 Clinical Expert Opinion To Inform Health Technology Assessment In Ireland .....	s177
PD221 Health Regulation And Health Technology Assessment: Brazilian Experience In Developing Actions For Health Regulation.....	s177
PD222 Balancing Patient Preferences With Feasible Healthcare Delivery: Using Discrete Choice Experiments Alongside Knowledge Exchange To Inform Care Pathways.....	s178
PD223 Early Dialogue With Researchers: The Case Of The OPTIBIO Study, Innovating From The Investigation Stages .....	s178
PD224 Evaluating Participant Satisfaction In Health Technology Assessment Reports: A Survey Study In Catalonia, Spain.....	s179
PD225 Implementation Of Hospital-Based Health Technology Assessment For Innovative And Expensive Medical Devices In A French Teaching Hospital.....	s179
PD226 Integration Of Patient And Clinician Insights Into The European Union Joint Scientific Consultations And Joint Clinical Assessments.....	s180
PD227 Qualitative Assessment Of The Value Of The Magnetic Resonance Linear Accelerator To Guide Decisions On Its Optimal Use.....	s180
PD228 Standardized Open Access Reporting Of Health Technology Assessment And Stakeholder Involvement.....	s181
PD229 “It’s All About Layers”: Painting The Picture Of Health Inequalities For Health Technology Assessment.....	s181
PD230 The VALUE Project: Multistakeholder Assessment For A Value-Based Prevention Of Vaccine-Preventable Lower Respiratory Tract Diseases.....	s182
PD231 A New Way Of Identifying And Selecting Health Technology Assessment Topics: Using Social Media And Citizen Involvement .....	s182
PD232 A New Process For Patients And Caregivers To Suggest Health Technologies For Funding Consideration In Singapore .....	s183
PD233 Does Patient Input Add Value To Healthcare Decision-Making? A Two-Year Reflection On Patient Involvement Processes In Singapore.....	s183
PD235 Impact Of A Consumer Panel To Inform Health Technology Assessments And Policy Development: The Singapore Experience.....	s184
PD237 Perspectives On Involvement In Health Technology Assessment: Insights From Representatives Of Persons With Mental Health Conditions .....	s184
PD238 Evolution Of The Consumer Evidence And Engagement Unit And Contribution To Consumer Input In Australian Health Technology Assessment Processes .....	s185
PD239 Assisted Daily Living: Stakeholder Involvement In Identifying Innovation Gaps, User Needs, And Potential Solutions.....	s185
PD240 Report Of Outcomes In Health Technology Assessment For Technologies In Ultrarare Diseases In The Brazilian Public Health System .....	s186
PD241 Supporting Patient Groups To Enhance Their Input To Health Technology Assessment.....	s186